Zelira Therapeutics (ASX:ZLD) launches oral care subsidiary in US

Company News

by Michael Luu

Global therapeutic medicinal cannabis company, Zelira Therapeutics (ASX:ZLD) has expanded into the dental health market by launching a scientifically formulated, hemp-derived cannabinoid-based oral care products subsidiary.

The company has joined forces with USDA Bio-preferred natural toothpaste developer SprinJene and Health and Natural Beauty USA Corp in this USA-based venture. The company aims to release to the US market a cannabinoid-containing toothpaste, its first over-the-counter product in the USA by Q4 2020.

In addition, Zelira Therapeutics (ASX:ZLD) remains confident that it is on track to deliver four more new products in global markets this year.

Shares in Zelira Therapeutics (ASX:ZLD) are trading 3.45 per cent higher at 6 cents

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.